Comparative Pharmacology
Head-to-head clinical analysis: RINVOQ LQ versus UPADACITINIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RINVOQ LQ versus UPADACITINIB.
RINVOQ LQ vs UPADACITINIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Janus kinase (JAK) inhibitor; selectively inhibits JAK1 and JAK3, modulating cytokine signaling involved in inflammation.
Upadacitinib is a selective and reversible Janus kinase (JAK) inhibitor. It preferentially inhibits JAK1 over JAK2, JAK3, and TYK2. By inhibiting JAK1, it modulates the signaling of multiple cytokines (e.g., IL-6, IL-2, IL-15, and interferons) involved in inflammatory pathways.
15 mg orally once daily; may increase to 30 mg once daily for inadequate response in certain conditions (e.g., rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, ulcerative colitis, Crohn's disease).
15 mg orally once daily for rheumatoid arthritis; 15 mg once daily for psoriatic arthritis; 15 mg once daily for ankylosing spondylitis; 15 mg once daily for atopic dermatitis; 45 mg once daily for 8 weeks then 15 mg once daily for ulcerative colitis; 45 mg once daily for 8 weeks then 15 mg once daily for Crohn disease.
None Documented
None Documented
Terminal half-life 3.5-7.9 hours; at steady state, effective half-life ~4.5 hours, supports twice-daily dosing.
Terminal elimination half-life is approximately 9 hours (range 5–13 hours), supporting once-daily dosing.
Renal (24% unchanged, 20% as metabolites), biliary/fecal (48% as metabolites), total radiolabeled dose recovery ~96% over 14 days.
Renal (approximately 24% unchanged in urine), fecal (approximately 34% unchanged in feces); total recovery of radiolabeled dose: 88% (36% urine, 52% feces).
Category C
Category C
Janus Kinase (JAK) Inhibitor
Janus Kinase (JAK) Inhibitor